Новая ИИ-система предлагает персонализированные подходы к лечению нейродегенеративных заболеваний Translation: New AI System Offers Personalized Approaches to Treat Neurodegenerative Diseases

Researchers from Harvard Medical School have introduced an AI model capable of identifying precise gene-drug combinations that can reverse pathological conditions in human cells.

The PDGrapher system aims to tackle some of the most challenging issues in medicine, such as neurodegenerative diseases like Parkinson’s and Alzheimer’s, as well as rare conditions like X-linked dystonia-parkinsonism.

Unlike conventional computational tools that merely identify correlations, PDGrapher predicts gene-drug pairs for restoring normal cell function and provides mechanistic explanations of how these interventions might work.

Historically, the drug development process has been slow, expensive, and fraught with inaccuracies. This AI model has the potential to expedite timelines and reduce costs while also revealing new therapeutic pathways.

The Harvard team has begun testing PDGrapher on real biological datasets. Initial results indicate that the system can highlight promising gene-drug combinations that align with known therapeutic interventions, while also identifying novel pairs that have yet to be validated in the lab.

If proven effective in clinical trials, this approach could assist medicine in shifting from one-size-fits-all treatment regimens to personalized therapies based on each patient’s unique biology.

Notably, in June, a drug developed by artificial intelligence showed signs of efficacy in treating a severe lung disease.